Skip to main content

Table 4 Outcome measure scores at baseline T1 and T3 (including only people who contribute to complete case analysis)

From: Nurse-led advance care planning with older people who have end-stage kidney disease: feasibility of a deferred entry randomised controlled trial incorporating an economic evaluation and mixed methods process evaluation (ACReDiT)

Variable

Immediate (n = 10)

Deferred (n = 12)

 

Baseline T1

T3

Within group P

Baseline T1

T3

Within group P

Adjusted diff in meanb

(95% CI)

ANCOVA P

KDQOL-36â„¢

 Symptomsa

81.7 (17.1)

75.4 (13.3)

0.116

71.4 (20.7)

78.3 (19.2)

0.154

−9.3 (−20.7,2.1)

0.103

 Effectsa

89.1 (12.8)

78.4 (16.0)

0.024

68.0 (24.1)

73.4 (21.6)

0.084

−12.2 (−23.3,-1.1)

0.033

 Burdena

56.9 (19.6)

46.9 (23.8)

0.100

41.7 (23.9)

55.2 (25.7)

0.001

−22.6 (−36.0,-9.1)

0.002

 SF12 physicala

38.3 (4.7)

31.5 (9.5)

0.008

33.2 (11.2)

34.9 (13.0)

0.513

−8.4 (−15.8,-1.0)

0.029

 SF12 mentala

51.7 (6.2)

53.3 (6.9)

0.608

53.1 (10.7)

52.4 (6.9)

0.816

1.2 (−5.0,7.3)

0.698

CORE34

0.4 (0.4)

0.4 (0.3)

0.293

0.6 (0.3)

0.4 (0.3)

0.01

0.2 (−0.0,0.3)

0.056

SHAREDc

14.5 (7.8)

12.0 (5.7)

0.344

7.8 (4.0)

11.2 (6.0)

0.167

−4.5 (−17.3,8.3)

0.410

  1. aMean (standard deviation)
  2. bANCOVA adjusted for baseline values
  3. cData from 2 patients in immediate group and 6 in deferred group